2022/09/02 Boehringer, IL-36, Rare disease

U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults - Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares

成人の汎発性膿疱性乾癬のフレア（再燃）に対する初の治療オプションとして 、インターロイキン 36 (IL-36) シグナル伝達を阻害する抗体薬スペソリマブ（spesolimab）を米国FDAが承認